High Grade Glioma
97
34
40
29
Key Insights
Highlights
Success Rate
66% trial completion
Published Results
15 trials with published results (15%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.5%
15 terminated out of 97 trials
65.9%
-20.7% vs benchmark
1%
1 trials in Phase 3/4
52%
15 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 29 completed trials
Clinical Trials (97)
Dabrafenib and/or Trametinib Rollover Study
GD2-CAR T Cells for Pediatric Brain Tumours
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Targeted Pediatric High-Grade Glioma Therapy
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Study of Olutasidenib and Temozolomide in HGG
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
Glioma Supra Marginal Incision Trial
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma